Reducing Vaccination Disparities During a National Emergency Response: The US Mpox Vaccine Equity Pilot Program.

J Public Health Manag Pract

CDC Mpox Emergency Response Team (Mr Bautista, Drs Madera-Garcia, Carter, Schwitters, Carnes, and Prejean, and Ms Byrkit), National Center for HIV, Viral Hepatitis, STD, and TB Prevention (Mr Bautista and Drs Madera-Garcia, Carnes, and Prejean), Epidemic Intelligence Service (Dr Madera-Garcia), National Center for Immunization and Respiratory Diseases (Dr Carter), National Institute for Occupational Safety and Health (Dr Schwitters), and Office of Readiness and Response (Ms Byrkit), Centers for Disease Control and Prevention, Atlanta, Georgia.

Published: February 2024

Context: In response to the first reported mpox cases in May 2022, the US government implemented plans to bring testing, treatment, and vaccines to communities disproportionately affected by mpox-including the population of men who have sex with men (MSM) and Black/African American and Hispanic/Latino men, 2 subpopulations experiencing vaccination disparities. We describe the development and implementation of the US Mpox Vaccine Equity Pilot Program (MVEPP), characteristics of completed vaccination projects, and challenges that occurred. We also discuss opportunities for reducing vaccination disparities in future outbreaks.

Program: To address reported vaccination disparities, the US government launched MVEPP in 2 phases. Phase 1 centered around public events attended by large numbers of gay, bisexual, and other MSM, such as Pride festivals. Phase 2 asked health departments to propose mpox vaccination projects specifically aimed at reducing or eliminating racial/ethnic and other demographic disparities in mpox vaccination.

Implementation: MVEPP received 35 vaccination project proposals. We analyzed data from 22 completed projects that resulted in 25 675 doses of JYNNEOS administered. We note 3 innovative strategies that were implemented in several projects: direct collaboration with organizations providing services to MSM and transgender women; implementation of MVEPP projects in unique nonclinical community settings and at venues frequented by MSM and transgender women; and offering an array of services as part of mpox vaccination projects, rather than offering only mpox vaccination.

Evaluation: MVEPP highlighted the importance of recognizing and working to eliminate racial/ethnic and other disparities in access to medical countermeasures during a public health emergency. Jurisdictions developed and implemented innovative strategies to bring mpox vaccination and related services to communities disproportionately affected by mpox-including MSM and the subpopulations of Black/African American and Hispanic/Latino MSM. Lessons learned from MVEPP may inform efforts to reduce disparities during future public health responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10843777PMC
http://dx.doi.org/10.1097/PHH.0000000000001818DOI Listing

Publication Analysis

Top Keywords

vaccination disparities
16
vaccination projects
12
mpox vaccination
12
reducing vaccination
8
mpox
8
mpox vaccine
8
vaccine equity
8
equity pilot
8
pilot program
8
communities disproportionately
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!